



PRESS RELEASE
For Immediate Release
May 6, 2009

Media Contact:
Linda Batykefer
Marketing Coordinator
Tel: 412.241.7335 ext 269
Fax: 412.241.7311
batykefer@chemimage.com

**RDD EUROPE 2009 PLAYS HOST TO CHEMIMAGE'S ADVANCED
INGREDIENT-SPECIFIC PARTICLE SIZING™ TECHNOLOGY**

*Presentation of Wide-Field Raman Chemical Imaging Technology
Shows Better Accuracy and Precision of In Vitro Drug Particle Size Distribution*

PITTSBURGH, PA – Representatives from pharmaceutical companies developing nasal and pulmonary drug delivery systems who are attending RDD Europe 2009, May 19-22, in Lisbon, Portugal, can get a better look at how ChemImage's Wide-Field Raman Chemical Imaging technology can help them develop new drug products with greater speed and accuracy of drug particle size distribution measurements.

Ryan J. Priore, Ph.D., Senior Scientist, ChemImage Corporation, will lead the poster presentation, which will explore the competitive advantages the FALCON II™ Wide-Field Raman Chemical Imaging System provides. The FALCON II enables drug makers to perform wide-field hyperspectral imaging studies, especially Raman Chemical Imaging (RCI) applications, which allow customers or users to study particles in droplets of a nasal spray suspension or individual particles in pulmonary drug delivery systems. RCI and Ingredient-Specific Particle Sizing (ISPS™) enables user to distinguish the chemical identity, particle size and distribution of drug and other substances, as well as aggregation, and other characteristics of the material in the formulation.

Dr. Priore said "The competitive nature of the drug-development marketplace requires drug makers to seek new ways of proving the efficacy of their products, as well as to decrease the product's time-to-market." ChemImage's technology and ISPS method, in fact, was recently recognized on the cover of *Inhalation* magazine (www.inhalationmag.com), which depicted the image fidelity and an accompanying editorial discussing the application and particle size and distribution accuracy achieved via the FALCON II system.

RDD Europe attendees can also visit with ChemImage representatives to learn more about the technology at their trade show booth during the conference.

According to Priore, the technology allows generic drug manufacturers to lower the risk when going into clinical trials by providing them with additional bioequivalency data. All pulmonary and nasal drug developers and formulators can utilize Raman Chemical Imaging technology and services to perform *in vitro* drug particle size distribution measurements, as well as understand the stability of the formulation by assessing aggregates.

- MORE -



Innovators can also utilize the technology to develop hard to duplicate formulations. The value of the chemical image comes from the importance of knowing where drug particles are in relation to other materials and how they are distributed. This provides an opportunity for drug development and product advances, including use as part of batch release testing.

ChemImage Corporation, headquartered in Pittsburgh, is a world leader in Chemical Imaging technologies; provides instrumentation, software, laboratory services, and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Its state-of-the-art Chemical Imaging technology can help to reveal critical chemical and biological information about processes, products and services.

###